Please see full Prescribing Information.
VENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults:
VENCLEXTA®, VENCOMPASS® and their designs are registered trademarks of AbbVie Inc.